| Literature DB >> 25376093 |
Haruki Komatsu1, Jun Murakami, Ayano Inui, Tomoyuki Tsunoda, Tsuyoshi Sogo, Tomoo Fujisawa.
Abstract
BACKGROUND: The disease progression following hepatitis B virus (HBV) infection is associated with single-nucleotide polymorphisms (SNPs). However, the role of SNPs in chronic HBV infection in children remains unclear. Here, we investigate the association between SNPs and early spontaneous hepatitis B e antigen (HBeAg) seroconversion in children with chronic hepatitis B infection.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25376093 PMCID: PMC4230755 DOI: 10.1186/1756-0500-7-789
Source DB: PubMed Journal: BMC Res Notes ISSN: 1756-0500
Primers for amplification and sequencing
| SNP ID | sequence (5 'to 3') | ||
|---|---|---|---|
|
| External | forward | TCAACTTCTTCCACCCCATC |
| reverse | GGCACATGTTTCCACCTCTT | ||
| Internal | forward | GGGTGAGGAAACCAAATTCTC | |
| reverse | TGCACTTGCTGAAAGCTTCTT | ||
|
| External | forward | TGGAAACATGTGCCTGAGAA |
| reverse | CAGTGACGTGGACAAATTGC | ||
| Internal | forward | AAAGGAGCCTGGAACACATC | |
| reverse | CCTTAGGTCTCTGGGCCTTA | ||
|
| External | forward | CTGAACTCCAGCTGCCCTAC |
| reverse | CTCCCCGCTCTGAAATACTG | ||
| Internal | forward | AACTCCAGCTGCCCTACAAA | |
| reverse | GGATAAAAGGCTCAATGAAAGG | ||
|
| External | forward | GGGCCTGTTACACATGACACT |
| reverse | TGGATGCATTCAAAAGTCCA | ||
| Internal | forward | TGCCCCCAAATCAAGTTTAG | |
| reverse | TGGCACACAAAGAAAATGGT | ||
|
| External | forward | ACGCGAAATTGAGTTCTTGG |
| reverse | CAGGCATGGGTTTACTTGGT | ||
| Internal | forward | GGTAAGAGGGAAAGCCCAGT | |
| reverse | CTGTCTCCGAGATTCCCAAG | ||
|
| External | forward | TTGGCCAGAGTATGCTTTCA |
| reverse | TTTGCCCTGAGGTCTATGCT | ||
| Internal | forward | TATGCTTTCACCAACTTCCTTCAC | |
| reverse | GAGCTCCCTCTGGCAGGTT | ||
|
| External | forward | GTGCATATGTTTTCTGAC |
| reverse | GAGGCCCCTCACCCATGC | ||
| Internal | forward | AAGTAACACTTGTTCCTTGTAAAAGATTCC | |
| reverse | CGCTATAATTAAAGATGTGGGAGAATGCAA |
Figure 1Classification of the subjects based on hepatitis B e antigen seroconversion.
Patients characteristics in individual groups
| G1: Early (N = 52) | G2: Late or no seroconversion (N = 57) | Univariate | Multivariate | ||
|---|---|---|---|---|---|
| P value | P value | ||||
| Age at initial visit (year) | 0-10 (Median 2.8) | 0-44 (Median 28) | < 0.00005 | **** | |
| Gender (Male/Female) | 28/24 | 5/52 | < 0.00005 | 0.001 | |
| ALT level (IU/L) at initial visit | 10-725 (Median 80.5) | 7-767 (Median 23) | < 0.00005 | 0.489 | |
| Duration of follow-up period (year) | 1-21 (Median 10.0)* | 1-25 (Median, 6.0) | 0.6218 | 0.013 | |
| Age at HBe seroconversion | 1-10 (Median 6.5) | 21-34 (Median 25)** | Not done | Not done | |
| Serum HBV DNA level at last visit (log copies/mL) | 2.5-8.7 (Median 4.8)*** | 3.0-9.0 (Median 8.5) | < 0.00005 | 0.003 | |
| Transmission route | Mother-to-child | 43 | 37 | Mother-to-child | |
| Household contacts | 5 | 4 | v.s. Non Mother-to-child | ||
| Blood transfusion | 1 | 0 | 0.036 | 0.016 | |
| Unknown | 3 | 16 | |||
| HBV Genotype | A | 0 | 1 | Genotype C | |
| B | 7 | 10 | v.s. Non genotype C | ||
| C | 44 | 45 | 0.445 | 0.221 | |
| D | 1 | 1 |
*Data of 51 patients were available.
**Of the 57 patients, 17 patients archived seroconversion.
*** Of the 57 patients, 23 patients were positive for serum HBV DNA and the remaining 28 patients were negative for HBV DNA.
****Omitted from model in order to permit convergence to finite maximim likelihood estimates.
The results of the Hardy-Weinberg equilibrium proportions
| SNP ID | Genotype | No. of G1 early seroconversion genotype frequency (%) | P value | No. of G2 late or no seroconversion genotype frequency (%) | P value |
|---|---|---|---|---|---|
| IL-10-819 | TT | 24 (46.2) | 25 (43.9) | ||
| (rs1800871) | CT | 18 (34.6) | 0.126 | 22 (38.6) | 0.3116 |
| CC | 10 (19.2) | 10 (17.5) | |||
| IL-10-592 | AA | 23 (44.2) | 26 (45.6) | ||
| (rs1800872) | CA | 14 (26.9) | 0.003 | 21 (36.8) | 0.221 |
| CC | 15 (28.8) | 10 (17.5) | |||
| HLA-DPA1 | CC | 22 (42.3) | 34 (59.6) | ||
| (rs3077) | TC | 27 (51.9) | 0.267 | 22 (38.6) | 0.424 |
| TT | 3 (5.8) | 1 (1.8) | |||
| HLA-DPB1 | GG | 27 (51.9) | 26 (45.6) | ||
| (rs9277535) | AG | 17 (32.7) | 0.147 | 21 (36.8) | 0.221 |
| AA | 8 (15.4) | 10 (17.5) | |||
| HLA-DQB2 | GG | 43 (82.7) | 50 (87.7) | ||
| (rs7453920) | GA | 0 | 1.736 × 10−11 | 1 (1.8) | 4.409 × 10-10 |
| AA | 9 (17.3) | 6 (10.5) | |||
| HLA-DQB1 | AA | 18 (34.6) | 18 (31.6) | ||
| (rs2856718) | GA | 24 (46.2) | 0.913 | 30 (52.6) | 0.742 |
| GG | 10 (19.2) | 9 (15.8) | |||
| IL-28B | TT | 39 (75.0) | 44 (77.2) | ||
| (rs8099917) | GT | 10 (19.2) | 0.176 | 13 (22.8) | 0.752 |
| GG | 3 (5.8) | 0 |
Association between SNPs and HBeAg seroconversion using Akaike’s information criteria and chi-square test
| SNP ID | Dominant model | Recessive model | Recessive model | Genotype model | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| AIC | Chi-squire test | AIC | Chi-squire test | AIC | Chi-squire test | AIC | Chi-squire test | ||||
| (IM-DM) | P value | OR (95% CI) | (IM-DM) | P value | OR (95% CI) | (IM-DM) | P value | OR (95% CI) | (IM-DM) | P value | |
| IL-10-819 | −1.942 | 0.810 | 0.912 (0.428-1.941) | −1.948 | 0.820 | 1.119 (0.424-2.953) | −1.998 | 0.963 | 0.987 (0.569-1.723) | −3.808 | 0.909 |
| (rs1800871) | |||||||||||
| HLA-DPA1 | 1.289 | 0.070 | 2.016 (0.940-4.325) | −0.716 | 0.266 | 3.429 (0.345-34.042) | 1.216 | 0.073 | 1.743 (0.946-3.211) | −0.080 | 0.145 |
| (rs3077) | |||||||||||
| HLA-DPB1 | −1.567 | 0.510 | 0.777 (0.366-1.650) | −1.908 | 0.762 | 0.855 (0.309-2.362) | −1.565 | 0.510 | 0.828 (0.471-1.453) | −3.566 | 0.805 |
| (rs9277535) | |||||||||||
| HLA-DQB1 | −1.887 | 0.736 | 0.872 (0.392-1.938) | −1.777 | 0.636 | 1.270 (0.471-3.422) | −1.999 | 0.976 | 1.008 (0.589-1.727) | −3.509 | 0.782 |
| (rs2856718) | |||||||||||
| IL-28B | −1.928 | 0.788 | 1.128 (0.467-2.724) | 2.534 | 0.066 | ND | −1.253 | 0.387 | 1.413 (0.643-3.099) | 0.623 | 0.176 |
| (rs8099917) | |||||||||||
ND: no data.
Association between SNPs and HBeAg seroconversion using logistic regression model
| SNP (ID) | Dominant model | Recessive model | Genotype model | ||||||
|---|---|---|---|---|---|---|---|---|---|
| P value | OR (95% CI) | P value | OR (95% CI) | P value | OR (95% CI) | ||||
| IL-10-819 (rs1800871) | CT + CC/TT | 0.810 | 0.912 (0.428-1.941) | CC/TT + CT | 0.820 | 1.120 (0.424-2.953) | CT/TT | 0.909 | 0.852 (0.369-1.970) |
| CC/TT | 1.042 (0.368-2.948) | ||||||||
| IL-10-592 (rs1800872) | CA + CC/AA | 0.885 | 1.058 (0.497-2.252) | CC/AA + CA | 0.160 | 1.905 (0.768-4.726) | CA/AA | 0.306 | 0.754 (0.313-1.814) |
| CC/AA | 1.696 (0.638-4.504) | ||||||||
| HLA-DPA1 (rs3077) | TC + TT/CC | 0.070 | 2.016 (0.940-4.323) | TT/CC + TC | 0.257 | 3.429 (0.3457-33.999) | TC/CC | 0.141 | 1.897 (0.872-4.127) |
| TT/CC | 4.636 (0.454-47.397) | ||||||||
| HLA-DPB1 (rs9277535) | AG + AA/GG | 0.510 | 0.777 (0.366-1.650) | AA/GG + AG | 0.761 | 0.855 (0.309-2.362) | AG/GG | 0.805 | 0.780 (0.338-1.799) |
| AA/GG | 0.770 (0.263-2.256) | ||||||||
| HLA-DQB2 (rs7453920) | GA + AA/GG | 0.459 | 1.495 (0.514-4.352) | AA/GG + GA | 0.304 | 1.779 (0.587-5.395) | GA/GG | ND | ND |
| AA/GG | ND | ||||||||
| HLA-DQB1 (rs2856718) | GA + GG/AA | 0.736 | 0.872 (0.392-1938) | GG/AA + GA | 0.636 | 1.270 (0.471-3.422) | GA/AA | 0.782 | 0.80 (0.343-1.863) |
| GG/AA | 1.111 (0.365-3.380) | ||||||||
| IL-28B (rs8099917) | GT + GG/TT | 0.789 | 1.128 (0.467-2.724) | GG/TT + GT | ND | ND | GT/TT | ND | ND |
| GG/TT | ND | ||||||||
ND: no data.